

Appendix 1. Demographics of the patients by cohort and site.

	Hong Kong		India	
	TAHOD-LITE n=524	TAHOD n=270	TAHOD-LITE n=8263	TAHOD n=350
	n (%)	n (%)	n (%)	n (%)
Year of ART initiation				
2003-05	107 (20)	47 (17)	2046 (25)	119 (34)
2006-09	118 (23)	154 (57)	3379 (41)	104 (30)
2010-13	299 (57)	69 (26)	2838 (34)	127 (36)
Age				
≤30	112 (21)	37 (14)	1934 (23)	81 (23)
31-40	180 (34)	101 (37)	4104 (50)	188 (54)
41-50	135 (26)	85 (31)	1642 (20)	68 (19)
51+	97 (19)	47 (17)	583 (7)	13 (4)
Median [IQR]	39 [32, 47]	40 [34, 48]	36 [31, 41]	35 [31, 40]
Sex				
Male	414 (79)	231 (86)	5660 (68)	236 (67)
Female	109 (21)	39 (14)	2595 (31)	114 (33)
Transgender	1 (<0.2)	0 (-)	8 (<0.1)	0 (-)
Mode of HIV exposure				
Heterosexual	217 (41)	119 (44)	7667 (93)	339 (97)
Homosexual	213 (41)	116 (43)	41 (<0.5)	1 (<0.3)
Injecting drug user	25 (5)	4 (1)	52 (1)	1 (<0.3)
Other/Unknown	69 (13)	31 (11)	503 (6)	9 (3)
HCV (ever)				
Positive	41 (8)	10 (4)	56 (1)	3 (1)
Negative	441 (84)	250 (92)	1188 (14)	126 (36)
Not tested	42 (8)	10 (4)	7019 (85)	221 (63)
HBV (ever)				
Positive	49 (9)	27 (10)	136 (2)	13 (4)
Negative	442 (85)	235 (87)	1833 (22)	230 (66)
Not tested	33 (6)	8 (3)	6294 (76)	107 (30)
Pre-ART CD4 (cells/μL)				
≤50	175 (33)	87 (32)	1058 (13)	41 (12)
51-100	70 (13)	38 (14)	1230 (15)	44 (13)
101-200	75 (14)	63 (23)	2240 (27)	108 (31)
>200	164 (31)	80 (30)	2007 (24)	138 (39)
Not tested	40 (8)	2 (1)	1728 (21)	19 (5)
Median [IQR]	98 [30, 259]	116 [35, 215]	146 [72, 223]	178 [95, 255]
Pre-ART viral load (copies/mL)				
≤10 ⁵	189 (36)	135 (50)	374 (4)	88 (25)
>10 ⁵	260 (50)	121 (45)	467 (6)	102 (29)
Not tested	75 (14)	14 (5)	7422 (90)	160 (46)
Median [IQR]	134750 [46000, 390687]	94675 [34067, 252441]	129098 [29600, 406339]	114431 [30746, 411000]
First ART regimen				
NRTI+NNRTI	385 (73)	221 (82)	8015 (97)	341 (97)
NRTI+PI	132 (25)	44 (16)	228 (3)	7 (2)
Other	7 (1)	5 (2)	20 (<0.2)	2 (1)
Previous mono/dual therapy				
No	491 (94)	254 (94)	7873 (95)	331 (95)
Yes	33 (6)	16 (6)	390 (5)	19 (5)

Appendix 1. Demographics of the patients by cohort and site.

	Indonesia				Singapore			
	TAHOD-LITE n=761		TAHOD n=353		TAHOD-LITE n=1725		TAHOD n=149	
	n	(%)	n	(%)	n	(%)	n	(%)
Year of ART initiation								
2003-05	12	(2)	102	(29)	9	(1)	61	(41)
2006-09	163	(21)	112	(32)	699	(41)	44	(30)
2010-13	586	(77)	139	(39)	1017	(59)	44	(30)
Age								
≤30	330	(43)	145	(41)	295	(17)	18	(12)
31-40	310	(41)	134	(38)	492	(29)	46	(31)
41-50	90	(12)	58	(16)	474	(27)	51	(34)
51+	31	(4)	16	(5)	464	(27)	34	(23)
Median [IQR]	31	[28, 37]	32	[28, 39]	42	[34, 51]	43	[36, 50]
Sex								
Male	489	(64)	250	(71)	1607	(93)	118	(79)
Female	272	(36)	101	(29)	116	(7)	31	(21)
Transgender	0	(-)	2	(1)	2	(<0.1)	0	(-)
Mode of HIV exposure								
Heterosexual	636	(84)	187	(53)	849	(49)	103	(69)
Homosexual	42	(6)	29	(8)	586	(34)	27	(18)
Injecting drug user	62	(8)	98	(28)	60	(3)	1	(1)
Other/Unknown	21	(3)	39	(11)	230	(13)	18	(12)
HCV (ever)								
Positive	21	(3)	49	(14)	74	(4)	5	(3)
Negative	268	(35)	86	(24)	1524	(88)	130	(87)
Not tested	472	(62)	218	(62)	127	(8)	14	(10)
HBV (ever)								
Positive	26	(3)	14	(4)	132	(8)	15	(10)
Negative	286	(38)	129	(37)	1445	(84)	130	(87)
Not tested	449	(59)	210	(59)	148	(8)	4	(3)
Pre-ART CD4 (cells/μL)								
≤50	268	(35)	147	(42)	536	(31)	42	(28)
51-100	82	(11)	43	(12)	211	(12)	12	(8)
101-200	92	(12)	58	(16)	282	(16)	29	(19)
>200	101	(13)	44	(12)	607	(35)	53	(36)
Not tested	218	(29)	61	(17)	89	(5)	13	(9)
Median [IQR]	51	[14, 157]	50	[13, 148]	126	[35, 267]	149	[32, 257]
Pre-ART viral load (copies/mL)								
≤10 ⁵	2	(<0.3)	34	(10)	380	(22)	20	(13)
>10 ⁵	0	(-)	57	(16)	429	(25)	31	(21)
Not tested	759	(99)	262	(74)	916	(53)	98	(66)
Median [IQR]	18850	[17000, 20700]	181909	[60349, 483993]	117000	[34292, 387000]	284500	[20689, 750001]
First ART regimen								
NRTI+NNRTI	756	(99)	352	(99)	1598	(93)	137	(92)
NRTI+PI	5	(1)	1	(<0.3)	105	(6)	4	(3)
Other	0	(-)	0	(-)	22	(1)	8	(5)
Previous mono/dual therapy								
No	756	(99)	318	(90)	1700	(99)	121	(81)
Yes	5	(1)	35	(10)	25	(1)	28	(19)

Appendix 1. Demographics of the patients by cohort and site.

	Vietnam		Cambodia	
	TAHOD-LITE n=1085	TAHOD n=526	TAHOD-LITE n=2073	TAHOD n=462
	n (%)	n (%)	n (%)	n (%)
Year of ART initiation				
2003-05	0 (-)	0 (-)	142 (7)	183 (40)
2006-09	0 (-)	0 (-)	1034 (50)	243 (53)
2010-13	1089 (100)	526 (100)	897 (43)	36 (8)
Age				
≤30	351 (32)	184 (35)	588 (28)	125 (27)
31-40	531 (49)	267 (51)	935 (45)	223 (48)
41-50	130 (12)	47 (9)	395 (19)	83 (18)
51+	73 (7)	28 (5)	155 (7)	31 (7)
Median [IQR]	32 [28, 37]	32 [29, 37]	35 [30, 41]	35 [30, 40]
Sex				
Male	676 (62)	333 (63)	971 (47)	245 (53)
Female	409 (38)	193 (37)	1099 (53)	217 (47)
Transgender	0 (-)	0 (-)	3 (<0.1)	0 (-)
Mode of HIV exposure				
Heterosexual	682 (63)	332 (63)	1902 (92)	457 (99)
Homosexual	15 (1)	1 (<0.2)	19 (1)	3 (1)
Injecting drug user	320 (29)	151 (29)	7 (<0.3)	0 (-)
Other/Unknown	68 (6)	42 (8)	145 (7)	2 (<0.4)
HCV (ever)				
Positive	411 (38)	217 (41)	111 (5)	26 (6)
Negative	652 (60)	305 (58)	1714 (83)	424 (92)
Not tested	22 (2)	4 (1)	248 (12)	12 (2)
HBV (ever)				
Positive	151 (14)	65 (12)	189 (9)	53 (12)
Negative	913 (84)	458 (87)	1657 (80)	398 (86)
Not tested	21 (2)	3 (1)	227 (11)	11 (2)
Pre-ART CD4 (cells/μL)				
≤50	391 (36)	166 (32)	522 (25)	145 (31)
51-100	104 (10)	67 (13)	273 (13)	76 (16)
101-200	173 (16)	83 (16)	448 (22)	117 (25)
>200	331 (31)	84 (16)	740 (36)	118 (26)
Not tested	86 (8)	126 (24)	90 (4)	6 (1)
Median [IQR]	101 [30, 222]	82 [27, 176]	145 [48, 242]	106 [35, 207]
Pre-ART viral load (copies/mL)				
≤10 ⁵	217 (20)	14 (3)	10 (<0.5)	2 (<0.4)
>10 ⁵	235 (22)	12 (2)	3 (<0.1)	14 (3)
Not tested	633 (58)	500 (95)	2060 (99)	446 (97)
Median [IQR]	113000 [32000, 370000]	31200 [1048, 227000]	18910 [399, 29300]	172000 [135000, 321000]
First ART regimen				
NRTI+NNRTI	1081 (99)	525 (99)	2036 (98)	454 (98)
NRTI+PI	3 (<0.3)	0 (-)	27 (1)	8 (2)
Other	1 (<0.1)	1 (<0.2)	10 (<0.5)	0 (-)
Previous mono/dual therapy				
No	1061 (98)	517 (98)	2055 (99)	458 (99)
Yes	24 (2)	9 (2)	18 (1)	4 (1)

Appendix 1. Demographics of the patients by cohort and site.

	South Korea			
	TAHOD-LITE n=283		TAHOD n=208	
	n	(%)	n	(%)
Year of ART initiation				
2003-05	51	(18)	65	(31)
2006-09	107	(38)	91	(44)
2010-13	125	(44)	52	(25)
Age				
≤30	82	(29)	56	(27)
31-40	87	(31)	74	(36)
41-50	56	(20)	47	(23)
51+	58	(20)	31	(15)
Median [IQR]	38	[30, 47]	37	[30, 45]
Sex				
Male	264	(93)	197	(95)
Female	19	(7)	11	(5)
Transgender	0	(-)	0	(-)
Mode of HIV exposure				
Heterosexual	73	(26)	39	(19)
Homosexual	115	(41)	98	(47)
Injecting drug user	1	(<0.4)	0	(-)
Other/Unknown	94	(33)	71	(34)
HCV (ever)				
Positive	3	(1)	3	(2)
Negative	242	(86)	165	(79)
Not tested	38	(13)	40	(19)
HBV (ever)				
Positive	11	(4)	11	(5)
Negative	248	(88)	164	(79)
Not tested	24	(8)	33	(16)
Pre-ART CD4 (cells/μL)				
≤50	38	(13)	31	(15)
51-100	27	(10)	18	(9)
101-200	57	(20)	36	(17)
>200	134	(47)	107	(51)
Not tested	27	(10)	16	(8)
Median [IQR]	212	[98, 313]	217	[99, 292]
Pre-ART viral load (copies/mL)				
≤10 ⁵	142	(50)	121	(58)
>10 ⁵	97	(34)	65	(31)
Not tested	44	(16)	22	(11)
Median [IQR]	66500	[16500, 274000]	45000	[12942, 200000]
First ART regimen				
NRTI+NNRTI	117	(41)	75	(36)
NRTI+PI	132	(47)	124	(60)
Other	34	(12)	9	(4)
Previous mono/dual therapy				
No	281	(99)	201	(97)
Yes	2	(1)	7	(3)